Top 5 Drug Type | Count |
---|---|
Small molecule drug | 8 |
Antibody drug conjugate (ADC) | 1 |
Probiotics | 1 |
Target- |
Mechanism Bacteria replacements [+1] |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. China |
First Approval Date01 Jan 1995 |
Target |
Mechanism RT inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. United States |
First Approval Date24 Jun 1994 |
Mechanism COX inhibitors [+2] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. South Korea |
First Approval Date29 Feb 1988 |
Start Date09 Dec 2024 |
Sponsor / Collaborator |
Start Date16 Oct 2024 |
Sponsor / Collaborator |
Start Date11 Sep 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Ceftriaxone Sodium ( PBPs ) | Intraabdominal Infections More | Approved |
Bacillus licheniformis(Dongbei Pharmaceutical Group Co. Shenyang No 1 Pharm Co. Ltd.) | Irritable Bowel Syndrome More | Approved |
Lidocaine ( SCNA ) | Tachycardia, Ventricular More | Approved |
Acetaminophen/Pseudoephedrine Hydrochloride/Chlorphenamine Maleate ( COXs x H1 receptor x α-adrenergic receptor ) | Influenza, Human More | Approved |
Lidocaine Hydrochloride ( SCNA ) | Tachycardia, Ventricular More | Approved |